Piper Jaffray Companies Reiterates $33.00 Price Target for Collegium Pharmaceutical (COLL)

Collegium Pharmaceutical (NASDAQ:COLL) received a $33.00 price objective from analysts at Piper Jaffray Companies in a report released on Monday. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Piper Jaffray Companies’ target price would suggest a potential upside of 39.71% from the stock’s current price.

Several other research firms have also recently commented on COLL. BidaskClub cut shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Friday, January 26th. Zacks Investment Research cut shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Needham & Company LLC upped their target price on shares of Collegium Pharmaceutical from $28.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, February 7th. Janney Montgomery Scott set a $26.00 target price on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Tuesday, February 6th. Finally, Jefferies Group upped their target price on shares of Collegium Pharmaceutical to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, December 5th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. Collegium Pharmaceutical has an average rating of “Buy” and a consensus target price of $27.17.

Collegium Pharmaceutical (COLL) traded up $1.85 during midday trading on Monday, reaching $23.62. 1,910,000 shares of the company’s stock traded hands, compared to its average volume of 619,791. Collegium Pharmaceutical has a 1 year low of $7.37 and a 1 year high of $26.77. The company has a market cap of $769.12 and a PE ratio of -7.95.

In other news, insider Alison B. Fleming sold 4,601 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $17.25, for a total value of $79,367.25. Following the completion of the sale, the insider now directly owns 28,513 shares of the company’s stock, valued at approximately $491,849.25. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Longitude Capital Partners, Ll sold 1,000,000 shares of the company’s stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $17.34, for a total transaction of $17,340,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,105,558 shares of company stock valued at $19,346,677. Company insiders own 25.76% of the company’s stock.

Several large investors have recently modified their holdings of the company. BlackRock Inc. lifted its stake in shares of Collegium Pharmaceutical by 4.2% in the 4th quarter. BlackRock Inc. now owns 1,965,566 shares of the specialty pharmaceutical company’s stock worth $36,285,000 after acquiring an additional 79,466 shares during the period. Macquarie Group Ltd. lifted its stake in shares of Collegium Pharmaceutical by 18.9% in the 3rd quarter. Macquarie Group Ltd. now owns 1,329,979 shares of the specialty pharmaceutical company’s stock worth $13,951,000 after acquiring an additional 211,288 shares during the period. Citadel Advisors LLC lifted its stake in shares of Collegium Pharmaceutical by 58.2% in the 4th quarter. Citadel Advisors LLC now owns 860,727 shares of the specialty pharmaceutical company’s stock worth $15,889,000 after acquiring an additional 316,694 shares during the period. Prudential Financial Inc. lifted its stake in shares of Collegium Pharmaceutical by 62.8% in the 3rd quarter. Prudential Financial Inc. now owns 557,050 shares of the specialty pharmaceutical company’s stock worth $5,843,000 after acquiring an additional 214,860 shares during the period. Finally, First Manhattan Co. acquired a new stake in shares of Collegium Pharmaceutical in the 4th quarter worth approximately $8,606,000. 82.40% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/12/piper-jaffray-companies-reiterates-33-00-price-target-for-collegium-pharmaceutical-coll.html.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply